Galapagos reports positive Phase I data with GLPG1205 in inflammatory disorders.
The study's goal was to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of oral single and multiple ascending doses of GLPG1205, which is being developed togetherA with Janssen Pharmaceutica. The trial enrolled 40 healthy volunteers at a clinical centre in Belgium.
The positive data encourages GalapagosA to initiate a Phase IIa study withA GLPG1205 in patients withA a chronic inflammatory bowel condition.
GLPG1205 is the first molecule that is clinically tested against this target, chief scientific officer (CSO)A Piet Wigerinck said, expressing his satisfaction with the study's outcome.A
|Printer friendly Cite/link Email Feedback|
|Date:||Dec 4, 2013|
|Previous Article:||Belgium's 11-mo bankruptcy number hits 2012 record.|
|Next Article:||Umicore JV opens automotive catalyst centre in Japan.|